The PFAS proposal: what is it, and where does it stand?
EU law increasingly regulates the use of PFAS, the so-called "forever chemicals". For MedTech and pharma companies, the implications are significant and some restrictions already apply.
Explore our latest insights, regulatory updates, and strategic reports for the life sciences sector.
9 results
EU law increasingly regulates the use of PFAS, the so-called "forever chemicals". For MedTech and pharma companies, the implications are significant and some restrictions already apply.
Axon drafted a cooperation agreement between an agro crop improvement company and four other companies, being both shareholders and competitors at the same time.
As a partner of StartLife, Axon assisted a feed company with the regulatory qualification of its technology. Our reasoned opinion serves as a key document for the company’s funding activities.
Our team has trained several multinationals on the implications of the Battery Regulation and the Packaging & Packaging Waste regulation, and regularly advises on these topics.
Our team advised a client on the registration process under REACH.
We have advised a start-up on the legal limitations and requirements related to the transport of dangerous substances.
We have advised a medical device manufacturer on the regulatory implications of the restriction on synthetic polymer microparticles for its products.
We have assisted a distributor of medical devices on questions pertaining to a cleaning solution regulated under the Biocidal Product Regulation.
Axon advised a Dutch joint venture, that is active within the agri-food and agricultural biotechnology sector, on the transfer of its assets to a German investment fund. The transferred assets involved patent rights, plant breeders’ rights, trade secrets and biological materials.